Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Thomas M Habermann

Showing results (11-20 of 374) with videos related to

Pageof 38
Sort By:
Mayo Clinic Proceedings|November 24, 2006
Education scholarshipThomas M Habermann, Terrence L Cascino
Annals of Lymphoma|April 8, 2021
Epidemiology of Marginal Zone LymphomaJames R Cerhan, Thomas M Habermann
Blood|November 9, 2021
How I treat cardiovascular complications in patients with lymphoid malignanciesJoerg Herrmann, Kristen B McCullough, Thomas M Habermann
Mayo Clinic Proceedings|February 13, 2002
Images and reflections from Mayo Clinic heritageThomas M Habermann, Renee E Ziemer, Jane C Lantz
Mayo Clinic Proceedings|November 7, 2003
Images and reflections from Mayo Clinic heritageThomas M Habermann, Renee E Ziemer, Jane C Lantz
International Journal of Dermatology|December 11, 2013
Lymphoma-associated skin cancer: incidence, natural history, and clinical managementJerry D Brewer, Thomas M Habermann, Tait D Shanafelt
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 2, 2016
Current Management Concepts: Primary Central Nervous System Lymphoma, Natural Killer T-Cell Lymphoma Nasal Type, and Post-transplant Lymphoproliferative DisorderTracy T Batchelor, Lim Soon Thye, Thomas M Habermann
The American Journal of Medicine|May 3, 2003
The well-being of physiciansTait D Shanafelt, Jeff A Sloan, Thomas M Habermann
Blood Advances|August 14, 2025
Non-DLBCL Monomorphic and Hodgkin Lymphoma PTLD: Clinical Insights and Treatment StrategiesSuheil Albert Atallah-Yunes, Arushi Khurana, Thomas M Habermann
British Journal of Haematology|April 5, 2024
Targeted therapy in Burkitt lymphoma: Small molecule inhibitors under investigationSuheil Albert Atallah-Yunes, Thomas M Habermann, Arushi Khurana
Pageof 38

Showing results (11-20 of 374) with videos related to

Sort By:
Pageof 38
Mayo Clinic Proceedings|November 24, 2006
Education scholarshipThomas M Habermann, Terrence L Cascino
Annals of Lymphoma|April 8, 2021
Epidemiology of Marginal Zone LymphomaJames R Cerhan, Thomas M Habermann
Blood|November 9, 2021
How I treat cardiovascular complications in patients with lymphoid malignanciesJoerg Herrmann, Kristen B McCullough, Thomas M Habermann
Mayo Clinic Proceedings|February 13, 2002
Images and reflections from Mayo Clinic heritageThomas M Habermann, Renee E Ziemer, Jane C Lantz
Mayo Clinic Proceedings|November 7, 2003
Images and reflections from Mayo Clinic heritageThomas M Habermann, Renee E Ziemer, Jane C Lantz
International Journal of Dermatology|December 11, 2013
Lymphoma-associated skin cancer: incidence, natural history, and clinical managementJerry D Brewer, Thomas M Habermann, Tait D Shanafelt
American Society of Clinical Oncology Educational Book. American Society of Clinical Oncology. Annual Meeting|June 2, 2016
Current Management Concepts: Primary Central Nervous System Lymphoma, Natural Killer T-Cell Lymphoma Nasal Type, and Post-transplant Lymphoproliferative DisorderTracy T Batchelor, Lim Soon Thye, Thomas M Habermann
The American Journal of Medicine|May 3, 2003
The well-being of physiciansTait D Shanafelt, Jeff A Sloan, Thomas M Habermann
Blood Advances|August 14, 2025
Non-DLBCL Monomorphic and Hodgkin Lymphoma PTLD: Clinical Insights and Treatment StrategiesSuheil Albert Atallah-Yunes, Arushi Khurana, Thomas M Habermann
British Journal of Haematology|April 5, 2024
Targeted therapy in Burkitt lymphoma: Small molecule inhibitors under investigationSuheil Albert Atallah-Yunes, Thomas M Habermann, Arushi Khurana
Pageof 38